Catalent Pharma Solutions agreed to acquire MaSTherCell Global, a contract development manufacturing organization (CDMO) subsidiary of Orgenesis, which anticipates that it will receive proceeds of approximately $126.7 million from the $315 million transaction. Orgenesis expects to use the net proceeds from the sale of MaSTherCell to continue to grow its point-of-care cell therapy business and to further the development of advanced therapy medicinal products.

“Both autologous and allogeneic cell therapies provide important new treatment options, with a rising number expected to gain regulatory approval over the coming years. Catalent is well-positioned to combine MaSTherCell’s expert teams and capabilities with our extensive resources and experience in scaling new platforms, and to help MaSTherCell build-out its development and commercial manufacturing capabilities,” says John Chiminski, chair and CEO of Catalent.

“We are very proud of the developments and accomplishments at MaSTherCell Global, which has become a best-in-class contract development and manufacturing organization servicing many of the leading cell and gene therapy companies. We are also grateful to Great Point Partners and SFPI-FPIM for their tremendous support. Since we completed our acquisition of MaSTherCell Global in 2015, the business has grown rapidly along with this burgeoning industry,” adds Vered Caplan, CEO of Orgenesis. “With Catalent’s expertise and resources, we believe MaSTherCell Global will be well positioned to continue on its current trajectory in order to meet the evolving needs of the industry.”